Anodyne| Nevirapine | |
|---|---|
 | |
| Molecular structure via molpic based on CDK |
| Conformer [] | |
|---|---|
| Conformer structure via JSmol | |
| Physical properties [] | |
|---|---|
| Molecular mass | 266.30 g/mol [1] |
| Appearance | Crystals from pyridine and water [1] |
| Melting point | 247-249 °C [1] |
| Solubility | >39.9 [ug/mL] (The mean of the results at pH 7.4) [1] |
| Predicted LogP | 2 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C15H14N4O [1] |
| IUPAC name | 2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one [1] |
| SMILES | CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4 [1] |
| InChI | InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20) [1] |
| InChIKey | NQDJXKOVJZTUJA-UHFFFAOYSA-N [1] |
| Dosing [] | |
|---|---|
| Elimination half-life | 45 hours |
Nevirapine
Nevirapine (also known as Viramune, BI-RG-587, Nevirapine anhydrous, 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, Viramune XR, BIRG 0587, BIRG587, Nevirapine, anhydrous, Nevirapine teva or 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one)
Chemistry
Salts []
Nevirapine is typically found in the form of its hemihydrate salt.
Stereochemistry []
Nevirapine is a achiral mixture
Legal status
- Australia: Nevirapine is a S4 substance.[3]
- United States: Nevirapine is a prescription only substance.
- European Union: Nevirapine is a prescription only substance.
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 4463, Nevirapine. Accessed July 4, 2025. https://pubchem.ncbi.nlm.nih.gov/compound/4463
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Nevirapine. UNII: 99DK7FVK1H. Global Substance Registration System. Accessed July 4, 2025. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/99DK7FVK1H
Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. June 21, 2022. Accessed July 4, 2025. https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017